Compare GRAB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRAB | ILMN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | GRAB | ILMN |
|---|---|---|
| Price | $5.20 | $128.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 15 |
| Target Price | $6.38 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 51.4M | 1.5M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.02 | ★ 4.46 |
| Revenue | $3,228,000,000.00 | ★ $4,288,000,000.00 |
| Revenue This Year | $23.99 | N/A |
| Revenue Next Year | $21.71 | $2.08 |
| P/E Ratio | $258.34 | ★ $28.91 |
| Revenue Growth | ★ 20.18 | N/A |
| 52 Week Low | $3.36 | $68.70 |
| 52 Week High | $6.62 | $153.06 |
| Indicator | GRAB | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 66.70 |
| Support Level | $5.15 | $124.27 |
| Resistance Level | $5.50 | $129.72 |
| Average True Range (ATR) | 0.19 | 3.90 |
| MACD | 0.01 | -0.41 |
| Stochastic Oscillator | 51.64 | 77.82 |
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.